Shaping the future of drug development with software solutions, innovative consulting and proven clinical research services.
Waltham, Massachusetts, USA
- Tweets 5,618
- Following 609
- Followers 1,084
- Likes 161
Workforce planning is often approached through the immediate needs of a role. But this can overlook something more fundamental. We discuss the broader questions sponsors should be asking to build teams that can continue to deliver well into the future.
hubs.ly/Q04ybTWd0
25
Parkinson’s disease is the second-most common neurodegenerative disease affecting over 11 million people globally. We discuss common endpoints used in clinical trials with an illustrative case study on how those endpoints may be analyzed.
hubs.ly/Q04ybT_L0
1
1
39
NICE has published its AI Delivery Plan. Dalia Dawoud and Manuel Cossio discuss what HTA, HEOR, and market access professionals need to know and how sponsors can prepare as NICE's vision moves from experimentation to implementation.
hubs.ly/Q04y5PyW0
25
In the fight against rare diseases, data is our most precious resource — and greatest challenge. We discuss how, through a case study on IOPD, propensity score methods can be used to estimate treatment effectiveness in this rare disease setting. hubs.ly/Q04y5P-K0
1
27
How do you build an FSP workforce that controls costs without compromising quality, capability, or delivery? Join our experts for a webinar that explores how smarter workforce models can strengthen delivery, optimize resources, and create lasting value: hubs.ly/Q04y0N220
39
On September 24, join Manuel Cossio and Nicolas Rouillé as they explore the applications delivering tangible impact across biometrics and R&D, from data management and document automation to statistical programming.
Register today! hubs.ly/Q04vzQ900
41
For sponsors planning umbrella, basket, or platform trials, recent FDA guidance has shifted the conversation toward what is required to ensure they are sufficiently rigorous for regulatory decision-making. We share what sponsors need to consider: hubs.ly/Q04vtZ7B0
1
30
The first EU JCA reports are beginning to highlight what teams need to consider as they prepare for JCA and subsequent national market access.
On September 17, join Cytel experts as they discuss practical insights from early JCA experience.
Register now! hubs.ly/Q04vqhGV0
2
34
Cytel will be at the 2026 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop event in Rockville, Maryland!
📍 Our experts will be at Table 5. Stop by and say hello!
Book a meeting: hubs.ly/Q04vkFV_0
See you in Rockville!
30
Cytel will be at DPHARM in Boston!
📍 Stop by Booth #518 to meet our experts!
Don't miss our presentation by Manuel Cossio, Head of AI Solutions.
Engineering Token Efficient AI for Clinical Development
September 15, 11:35AM
See you in Boston! hubs.ly/Q04tYxgC0
33
FDA's June 2026 draft guidance, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, raises critical questions for sponsors.
On September 10, Cytel experts will examine the guidance in detail.
Register today! hubs.ly/Q04tQt8K0
12
On September 3, Cytel experts will share practical experiences and lessons learned from a recent vaccine submission preparation, drawing on three years of retrospective CBER feedback.
Register today! hubs.ly/Q04sJYb-0
1
32
As AI becomes integrated into evidence synthesis and EU JCA workflows, evaluation should increasingly measure regulatory fluency — the ability to preserve scientific intent, methodological reasoning, and regulatory context across languages. bit.ly/4fF1k8F
2
34
The conversations at SCT and PSI made one thing clear: DMCs are evolving alongside the increasing complexity of clinical trials. We discusses key opportunities to modernize existing DMC models: hubs.ly/Q04rhs5z0
1
1
41
SDTM is standardized. Implementations are not! We discuss how, by analyzing metadata at scale, we can see patterns that are invisible in a single study, and how metadata may be one of the best tools we have to bring standards back into alignment. hubs.ly/Q04qFr9d0
1
1
39
Statistical Data Analysis Centers (SDAC) support far more than periodic DMC reviews. We detail how, from randomization oversight and event tracking to vendor collaboration and regulatory support, SDACs play an important role in maintaining trial integrity: hubs.ly/Q04qrrL40
32
The inclusion of AI in clinical research has long-reaching effects for clinicians, programmers, and statisticians. Our experts will shed some light on the future of clinical programming and biostatistics roles in our upcoming webinar. Register today! hubs.ly/Q04qcdvs0
1
68
At #JSM2026, Subhajit Sengupta will showcase a new feature of Cytel’s East Horizon™ platform designed to provide support for trial design.
A Retrieval-Augmented Conversational Assistant for Clinical Trial Design and Simulation
Aug 6, 8:35AM
hubs.ly/Q04qfzY50
23
At #JSM2026, Cytel's co-founder will present how Pareto algorithms and Pareto contour maps within a DSS can enable trial designers to select the best trial designs.
"Interactive Multicriteria Optimization for Clinical Trial Designs"
Aug 6, 9:20AM
hubs.ly/Q04pZVM20
26
The inclusion of AI in clinical research has long-reaching effects for clinicians, programmers, and statisticians. Our experts will shed some light on the future of clinical programming and biostatistics roles in our upcoming webinar. Register today! hubs.ly/Q04pHcQZ0
55